

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Grimes, et al.

Serial No. : 10/813,336

Filed : March 29, 2004

For : GASTRIN HORMONE IMMUNOASSAYS

Examiner : Christine E. Foster

Group Art Unit : 1641

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450

Algis Anilionis, Ph.D.

Name of Sender

PTO Reg. No.

2 28 06

Signature

Date of Signature

Mail Stop Amendment Commissioner for Patents U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

DECLARATION CONCERNING BIOLOGICAL DEPOSITS

Sir:

This Declaration Concerning Biological Deposits is submitted in connection with the above-captioned application.

2/8/2006 4:31 PM (2K) NEWYORK 5433461 v1 [5433461_1.DOC]

I, John M. McCafferty, declare the following:

- I. Biological deposits of the following hybridomas were made with the American Type
 Culture Collection (ATCC, Manassas, VA) on March 25, 2004:
 - 1. Hybridoma 400-1 producing MAb 400-1, assigned ATCC accession number PTA-5889.
 - 2. Hybridoma 400-2 producing MAb 400-2, assigned ATCC accession number PTA-5890.
 - 3. Hybridoma 400-3 producing MAb 400-3, assigned ATCC accession number PTA-5891.
 - 4. Hybridoma 400-4 producing MAb 400-4, assigned ATCC accession number PTA-5892.
 - 5. Hybridoma 401-2 producing MAb 401-2, assigned ATCC accession number PTA-5893.
 - 6. Hybridoma 445-1 producing MAb 445-1, assigned ATCC accession number PTA-5894.
 - 7. Hybridoma 445-2 producing MAb 445-2, assigned ATCC accession number PTA-5895.
 - 8. Hybridoma 458-1 producing MAb 458-1, assigned ATCC accession number PTA-5896.
- II. A Receipt for the above deposits is attached as Exhibit A.
- III. The Hybridoma deposits, PTA-5889, PTA-5890, PTA-5891, PTA-5892, PTA-5893, PTA-5894, PTA-5895, and PTA-5896, were made under the terms of the Budapest Treaty in connection with US Patent Application Serial No. 10/813,336 filed March 29, 2004, and co-filed US Provisional Patent Application Serial No. 60/557,759, the benefit

1102865-0046

of which is claimed by US Patent Application Serial No. 11/093,724 filed March 29,

2005.

IV. The Hybridoma deposits, PTA-5889, PTA-5890, PTA-5891, PTA-5892, PTA-5893,

PTA-5894, PTA-5895, and PTA-5896, will be irrevocably and without restriction

released to the public upon issuance of a patent from any of the above-listed applications,

or any Continuation, Continuation-in-part or Divisional application therefrom.

I hereby declare that all statements made herein of my own knowledge are true and that

all statements made on information and belief are believed to be true; and further that these

statements were made with the knowledge that willful false statements and the like so made are

punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

Code and that such willful false statements may jeopardize the validity of the applications or any

patent issued thereon.

Dated: 27 FEB 2000

Respectfully submitted,

John M. McCafferty

Vice President and

Corporate Counsel

Aphton Corporation

2/8/2006 4:31 PM (2K) NEWYORK 5433461 v1 [5433461_1.DOC]

3



10801 University Blvd • Manassas, VA 20110-2209 • Telephone: 703-365-2700 • FAX: 703-365-2745

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3 AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.

To: (Name and Address of Depositor or Attorney)

Aphton Corporation Attn: Stephen Grimes 26 Harter Avenue Suite 14 Woodland, CA 95776

Deposited on Behalf of: Aphton Corporation

Identification Reference by Depositor:

Patent Deposit Designation

Mouse Hybridoma Cell Line: 400-1 Mouse Hybridoma Cell Line: 400-2	PTA-5889 PTA-5890
Mouse Hybridoma Cell Line: 400-3	PTA-5891
Mouse Hybridoma Cell Line: 400-4	PTA-5892
Mouse Hybridoma Cell Line: 401-2	PTA-5893
Mouse Hybridoma Cell Line: 445-1	PTA-5894
Mouse Hybridoma Cell Line: 445-2	PTA-5895
Mouse Hybridoma Cell Line: 458-1	PTA-5896

The deposits were accompanied by: __ a scientific description a proposed taxonomic description indicated above. The deposits were received March 25, 2004 by this International Depository Authority and have been accepted.

AT YOUR REQUEST: X We will inform you of requests for the strains for 30 years.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested April 9, 2004. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:

Marie Harris, Patent Specialist, ATCC Patent Depository

Date: May 5, 2004

cc: Dimitrios Drivas